[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-remodeling-ventricular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-remodeling-ventricular":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100509241","left-bundle-brancharea-pacing-to-avoid-pacing-induced-cardiomyopathy-100509241",false,"NCT05910866","LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy","LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy: the LEAP-CAR Prospective, Randomized Trial","LEAP-CAR","Inclusion Criteria:\n\n* advanced AVB (frequent 2° degree or 3° degree AVB, atrial fibrillation - AF - with advanced AV block) and preserved or slightly reduced LVEF (\\>45%)\n\nExclusion Criteria:\n\n* LVEF ≤45%\n* signs or symptoms of heart failure at enrollment\n* unstable angina or acute coronary syndrome \\\u003C3 months\n* percutaneous coronary intervention or coronary-artery bypass surgery \\\u003C3 months\n* life expectancy \\\u003C6 months\n* previous hospitalization for heart failure\n* evidence of pulmonary artery hypertension of any origin\n* valvular disease greater than moderate\n* previous heart transplant pregnancy","ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","LEAP-CAR will evaluate the benefit of left bundle branch area pacing (LBBAP), comparing to conventional right ventricular pacing (RVP), in preventing pacing-induced cardiomyopathy (PICM) in patients undergoing pacemaker implant for advanced (2° or 3° degree) atrioventricular block, with baseline left ventricular ejection fraction (LVEF) \\>45%.\n\nLEAP-CAR is a randomized, prospective, double blind clinical trial.",[27,28,29,30,31],"Bradycardia","Heart Failure","Pacemaker-Induced Cardiomyopathy","Conduction Block, Atrioventricular","Cardiac Remodeling, Ventricular",[33,34,35,36],"left bundle branch area pacing","conduction system pacing","physiologic pacing","pacing-induced cardiomyopathy","RECRUITING","2024-01-29",{"date":40,"type":41},"2024-01-30","ACTUAL",{"date":43,"type":41},"2023-06-10",{"date":45,"type":21},"2026-06-10",{"name":47,"class":48},"Azienda Ospedaliero Universitaria Maggiore della Carita","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100471806","speckle-tracking-echocardiography-as-a-tool-for-early-diagnosis-of-impaired-fetal-growth-twin-pregnancies-100471806","NCT05423665","Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies","Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth in Twin Pregnancies","HEART","Inclusion Criteria:\n\n* Singleton or dichorionic twin pregnancy\n* Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit\n* Women ≥ 18 years\n\nExclusion Criteria:\n\n* Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy\n* Fetal arrhythmia\n* Known fetal congenital or genetic abnormalities\n* Any suspicion of congenital fetal anomalies that might influence fetal cardiac function\n* Pre-existing maternal hypertensive disease\n* Autoimmune disease including systemic lupus erythematosus\n* History of stillbirth\n* Diabetes mellitus (mother)","FEMALE","45 Years",{"count":61,"type":21},360,"OBSERVATIONAL","In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.",[65,31,66,67],"Fetal Growth Restriction","Placental Insufficiency","Air Pollution","2023-09-25",{"date":70,"type":41},"2023-09-26",{"date":72,"type":41},"2023-06-22",{"date":74,"type":21},"2028-02-01",{"name":76,"class":48},"University Hospital, Ghent",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":62,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":49},"100453061","pforzheim-tricuspid-valve-registry---outcomes-of-percutaneous-tricuspid-valve-repair-100453061","NCT05179616","Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair","Pforzheim Tricuspid Valve Registry: A Real-world Observational Trial Evaluating Outcomes in Patients Treated With the Abbott TriClip™ Device in Helios Klinikum Pforzheim","Inclusion Criteria:\n\n* Subjects (\\>=18 years age) have severe tricuspid regurgitation and are symptomatic despite medical therapy.\n* Subjects eligible to receive the TriClip™\n* Subjects must provide written informed consent prior to study procedure.\n\nExclusion Criteria:\n\n* Subjects participating in another clinical study that may impact the follow-up or results of this study.",{"count":85,"type":21},200,"12 Months","The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.",[89,90,31,91],"Tricuspid Regurgitation","Right Heart Failure","Cardiac Remodeling, Atrial","2023-09-20",{"date":94,"type":41},"2023-09-22",{"date":96,"type":41},"2020-11-30",{"date":98,"type":21},"2026-11-30",{"name":100,"class":48},"Helios Klinikum Pforzheim"]